Apr 21, 2014 7:00am EDT Can-Fite Initiates the Development of an A3AR Biomarker Test Kit to Predict Patients' Response to Company's Drugs
Mar 17, 2014 7:00am EDT Can-Fite: Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel
Mar 03, 2014 7:00am EST Can-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program
